Investigator-initiated, open-label trial of ustekinumab for the treatment of moderate-to-severe palmoplantar psoriasis

By Au Shiu-Chung  

Journal of Dermatological Treatment, Vol. 24, Iss. 3, 2013-06 ,pp. : 179-187

Informa Healthcare

Access to resources Recommend Favorite

Psoriasis responds to intralesional injections of alefacept and may predict systemic response to intramuscular alefacept: Interim results of a single-arm, open-label study

By Gattu Shilpa   Busse Kristine   Bhutani Tina   Chiang Charles   Nguyen Thao   Becker Emily   Koo John Y. M.  

Journal of Dermatological Treatment, Vol. 23, Iss. 2, 2012-04 ,pp. : 103-108

Informa Healthcare

Access to resources Recommend Favorite

Palmoplantar Pustular Psoriasis: Successful Therapy with Efalizumab after Non-response to Infliximab

By Wozel Gottfried   Vitéz Lilla  

Acta Dermato-Venereologica, Vol. 88, Iss. 2, 2008-01 ,pp. : 169-170

Medical Journals Limited

Access to resources Recommend Favorite

Alefacept: Its safety profile, off-label uses, and potential as part of combination therapies for psoriasis

By Scheinfeld Noah  

Journal of Dermatological Treatment, Vol. 18, Iss. 4, 2007-01 ,pp. : 197-208

Informa Healthcare

Access to resources Recommend Favorite

Onset of palmoplantar pustular psoriasis while on adalimumab for psoriatic arthritis: A ‘class effect’ of TNF-α antagonists or simply an anti-psoriatic treatment adverse reaction?

By Rallis Efstathios   Korfitis Chrysovalantis   Stavropoulou Evgenia   Papaconstantis Markos  

Journal of Dermatological Treatment, Vol. 21, Iss. 1, 2010-01 ,pp. : 3-5

Informa Healthcare

Access to resources Recommend Favorite